Updates are available Correction dated 2021-05-20
Click to view Correction: https://doi.org/10.1007/s13300-021-01073-3
Updates are available Correction dated 2021-08-31
Click to view Correction: https://doi.org/10.1007/s13300-021-01134-7
-
Authors
Nakamura, Ichiro
Maegawa, Hiroshi
Tobe, Kazuyuki
Uno, Satoshi
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02479399 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM
https://doi.org/10.1007/s13300-021-01042-w
Safety and effectiveness of ipragliflozin in elderly versus non-elderly Japanese type 2 diabetes mellitus patients: 12 month interim results of the STELLA-LONG TERM study
https://doi.org/10.1080/03007995.2019.1647503
Real-world evidence for long-term safety and effectiveness of ipragliflozin in treatment-naïve versus non-naïve Japanese patients with type 2 diabetes mellitus: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM)
https://doi.org/10.1007/s13340-021-00501-w
-
Funding
Funding for this research was provided by:
Astellas Pharma Inc.
- License Information
-
More Information
Article History
Received: 22 December 2020
Accepted: 26 February 2021
First Online: 17 March 2021
Change Date: 20 May 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13300-021-01073-3
Change Date: 31 August 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13300-021-01134-7
